Guest guest Posted July 24, 2001 Report Share Posted July 24, 2001 July 2001 DRAFT: 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus ATIS Guidelines page http://hivatis.org/trtgdlns.html Direct link to PDF of document http://www.hivatis.org/guidelines/OIGuidelinesJuly2001.pdf " Major changes in the guidelines since 1999 include: Higher level ratings have been provided for discontinuing primary prophylaxis for PCP and MAC when CD4+ T lymphocytes have increased to >200 cells/µL and >100 cells/µL, respectively, for 3 months in response to HAART (AI), and a new recommendation to discontinue primary toxoplasma prophylaxis has been provided when the CD4+ T lymphocyte count has increased to >200 cells/µL for 3 months (AI). · Secondary PCP prophylaxis should be discontinued in patients whose CD4+ counts have increased to >200 cells/µL for 3 months as a consequence of HAART (BII). · Secondary prophylaxis for disseminated MAC may be discontinued in patients with a sustained (e.g., 6 months) increase in CD4+ count to >100cells/µL in response to HAART if they have completed 12 months of MAC therapy and have no symptoms or signs attributable to MAC (CIII). · Secondary prophylaxis for toxoplasmosis and cryptococcosis may be discontinued in patients with a sustained increase in CD4+ counts (e.g. >6 months) to >200 cells/µL and greater than >100-200cells/µL respectively, in response to HAART if they have completed their initial therapy and have no symptoms or signs attributable to these pathogens (CIII). · The importance of screening all HIV-infected individuals for hepatitis C virus (HCV) is emphasized(BIII). · Additional information about transmission of human herpesvirus 8 infection (HHV-8) is provided. · New information on drug interactions is provided, especially with regard to rifamycins and antiretroviral drugs. · Revised recommendations for immunization of HIV exposed/infected adults and children are provided. " _______________________ Comments should be directed to : Henry Masur MD, Clinical Center 7D43, National Institutes of Health, Bethesda, MD 20892 or to hmasur@... until September 1, 2001. ______________________________ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.